

UNITED STATES  
**SECURITIES AND EXCHANGE COMMISSION**  
WASHINGTON, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **April 2022**

Commission File Number: **001-36187**

**EVOGENE LTD.**

(Translation of Registrant's Name into English)

**13 Gad Feinstein Street, Park Rehovot, Rehovot  
P.O.B 4173, Ness Ziona, 7414002, Israel**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): \_\_\_\_

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): \_\_\_\_

---

## CONTENTS

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 [AgPlenus Investor Presentation.](#)

---

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD.  
(Registrant)

Date: April 26, 2022

By: /s/ Yaron Eldad  
Yaron Eldad  
Chief Financial Officer

---

---



# Forward-Looking Statements

This presentation contains "forward-looking statements" relating to future events, and AgPlenus (the "Company") and its parent, Evogene Ltd. ("Evogene", and collectively "we", "us", "our"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, growing market's expectations, challenges, business model and potential revenue stream, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".


Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

# Agenda

- Company introduction
- Business model
- Product pipeline
- Technology
- Milestone roadmap









We design next-generation, effective and sustainable crop protection products by leveraging predictive biology & chemistry



# Growing market for crop protection products with need for innovation



Source: [www.globenewswire.com/news-release/2021/02/02/2168067/0/en/Crop-Protection-Chemicals-Market-Size-Share-Will-Reach-to-USD-90-Billion-by-2026-Facts-Factors.html](http://www.globenewswire.com/news-release/2021/02/02/2168067/0/en/Crop-Protection-Chemicals-Market-Size-Share-Will-Reach-to-USD-90-Billion-by-2026-Facts-Factors.html)



Source: [www.teccia.org/files/teccia/News/Phillips%20McDougall%20Evolution%20of%20the%20Crop%20Protection%20Industry%20since%201960.pdf](http://www.teccia.org/files/teccia/News/Phillips%20McDougall%20Evolution%20of%20the%20Crop%20Protection%20Industry%20since%201960.pdf)

**Lack of new Mode-of-Action (MoAs) for 3 decades**  
**Major Ag companies have failed to meet the demand for innovation**





Glyphosate-resistant  
Palmer Amaranth

## Herbicide resistant weeds have flourished

- Overuse of existing MoAs has generated selection pressure
  - 263 herbicide-resistant weed species have evolved\*
- Substantial economic cost to farmers
  - Increase costs and reduce yields
  - United States: Soybeans: \$35/acre additional costs\*\*

### The challenge:


There have been no commercial herbicides with a new MoA for over 30 years\*\*\*

Sources: \* <https://weedsociety.org/Home.aspx>

\*\* [Herbicide resistant weeds cost farmers millions | Farm Progress](#)

\*\*\* [Focus on Weed Control: Herbicides as Weed Control Agents: State of the Art. I. Weed Control Research and Safener Technology: The Path to Modern Agriculture - PMC \(nih.gov\)](#)

# AgPlenus' target-based technology addresses the challenges



AgPlenus' Technology

Powered by:

evogene  
EVOLVING BIOLOGY

Chem  
Pass<sup>AI</sup>

## Innovative & experienced management team



**Dr. Brian Ember**  
CEO

Previous positions:

- Biotals, Head of Global Portfolio Management and Head of Marketing
- AgriMetis,
- Business Development



**Dr. Merav Beiman**  
VP R&D

Previous positions:

- ImmPACT-Bio, CEO
- Ferring, R&D
- Compugen, R&D
- QBI, R&D



**Mirit Ram**  
VP of Project Management

Previous positions:

- Evogene, PM
- FMC, PM
- HP

## Experienced board of directors



**Ofer Haviv**  
Chairman of the board

- Evogene, President & CEO



**Robert A. Woods**

- Marrone Bio Innovations, Inc., Chairman
- Bioenterprise capital private equity
- Previously, Syngenta, President USA




**Eran Kosover**

- Previously AgPlenus Ltd., CEO
- Evogene EVP & GM Crop Protection, Evogene VP of collaborations,
- Atera Networks

# Agenda

- Company introduction
- **Business model**
- Product pipeline
- Technology
- Milestone roadmap



# Crop protection industry

- Dominated by Major ag-chemical companies




- 62%\* of ag-chemical crop protection market share (Bayer, BASF, Corteva, Syngenta)
  - Pace of innovation and new product introductions have slowed
- 
- Looking to smaller, ag-tech companies to develop new small-molecule candidates
    - AgPlenus is leading the integration of computational technology to discover small molecules
    - Focusing on developing products with new MoAs

\* Source: <https://belonging.berkeley.edu/era-corporate-consolidation-and-end-competition>




# Product development stages




# Value creation through product development process

As products are developed to a greater extent, technical risks decline creating more value.



# Business model & potential revenue stream



# Corteva collaboration



- **Develop new MoA herbicides to target resistant weeds**

- Started in March 2020
- AgPlenus will discover and optimize herbicide candidates
- Corteva will conduct testing and product development




- **License to Corteva**

- Corteva has exclusive license to products of collaboration
- AgPlenus receives research fees, milestones and royalties upon commercialization

# Agenda

- Company introduction
- Business model
- **Product pipeline**
- Technology
- Milestone roadmap





# Products under development



## Herbicides

- Novel MoA herbicides
- Optimize existing herbicides to overcome resistance
- High value crops – Corn, Soybean, Cereals, Rice, Cotton, Canola ...
- Addressable market expected (2022): \$39B USD \*




## Insecticides

- Novel SoA (Site-of-Action)
- Addressable market expected (2022): \$19B \*\*

Sources \* <https://signicent.com/herbicide-market-crop-protection-report/#:-:text=The%20global%20herbicides%20market%20was%20valued%20at%20USD,demand%20for%20food%2C%20and%20adopting%20better%20farming%20practices>  
\*\* <https://www.marketsandmarkets.com/Market-Reports/insecticide-market-142427569.html>

# AgPlenus product pipeline



APTH-AgPlenus target herbicide, APH-AgPlenus herbicide, APTI-AgPlenus target Insecticide, S-Scaffold

## APH 1 (APTH1/Scaffold1) – New MoA herbicide reached Lead stage

- Broad-spectrum weed control at commercial dosage rates
- Effective against resistant weed strains – including *Palmer Amaranth*



SETVI  
ALOMY  
DIGSA  
ECHCO  
EUPHE  
ABUTH  
ANBEL  
AMAPA



SETVI  
ALOMY  
DIGSA  
ECHCO  
EUPHE  
ABUTH  
ANBEL  
AMAPA



SETVI  
ALOMY  
DIGSA  
ECHCO  
EUPHE  
ABUTH  
ANBEL  
AMAPA

(16DAA) (Rehovot, Israel)


# APH 1 (APTH1/Scaffold1)

New MoA Herbicide active at commercial concentrations




# APH 1 (APTH1/Scaffold1) - Product candidate efficacy

- Efficacy** • APH 1 displays herbicidal activity on multiple important weed species, both grasses and broad-leaves



- Strong activity on a broad panel of target weeds
- No weed recovery from herbicide effect

LTP single dose (0.75 kg/ha), pre, TP2 (18DAA)



- Strong activity in pre-application on both grasses and broad leaves




**Broad activity, pre and post application**




# Agenda


- Company introduction
- Business model
- Product pipeline
- **Technology**
- Milestone roadmap



# AgPlenus technology empowered by Evogene's ChemPass AI




# Computational prediction of multiple product attributes




\* In-process / Planned

# From Target to an Optimized Lead




# Experimental pipeline up to Lead stage





# Agenda

- Company introduction
- Business model
- Product pipeline
- Technology
- Milestone roadmap



# Expected main near-term value drivers

## 2022

---

- New MoA herbicides –
- Enter an additional collaboration agreement
- New MoA herbicide –
- Expand data package for APTH1, AgPlenus' leading new MoA protein for the development of novel herbicides

## 2023

---

- New MoA herbicides –
- Reach milestone in one of the ongoing collaborations
- New MoA fungicide –
- Initial greenhouse readouts



# We are AgPlenus

Creating effective  
and sustainable  
crop protection  
products







**THANK YOU**

---

